In the article titled "A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy" \[[@B1]\], the authors would like to clarify why the SurePath™ method was used in urine from diabetic nephropathy patients. The following text should be replaced with the addition of two missing references, 26 and 27 \[[@B2], [@B3]\]:

Original:

A similar technique of liquid-based cytology currently used in the cytodiagnosis of cervical cancer has replaced the conventional Pap smear cytology \[25\]. Our method using SurePath™ is simple and improved the detection of podocytes in urine samples.

Revised:

A similar technique of liquid-based cytology currently used in the cytodiagnosis of cervical cancer has replaced the conventional Pap smear cytology \[25\]. Additionally, a similar approach has been used to detect WT-1-positive cells in kidney disease \[26\], and its application in the diagnosis of kidney disease has also been studied \[27\]. Our method using SurePath™ is simple and is expected to improve the detection of podocalyxin-positive podocytes in urine samples compared with our conventional method.
